427 related articles for article (PubMed ID: 17021808)
41. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy.
Cortés-Romera M; Sabaté-Llobera A; Mercadal-Vilchez S; Climent-Esteller F; Serrano-Maestro A; Gámez-Cenzano C; González-Barca E
Clin Nucl Med; 2014 Jan; 39(1):e46-52. PubMed ID: 23640215
[TBL] [Abstract][Full Text] [Related]
42. 18F-FDG PET/CT evaluation of lymphoma with renal involvement: comparison with renal carcinoma.
Ye XH; Chen LH; Wu HB; Feng J; Zhou WL; Yang RM; Bu ZB; Ding Y; Guan J; Wang QS
South Med J; 2010 Jul; 103(7):642-9. PubMed ID: 20531045
[TBL] [Abstract][Full Text] [Related]
43. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
45. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
[TBL] [Abstract][Full Text] [Related]
46. PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique.
Guo W; Hao B; Chen HJ; Zhao L; Luo ZM; Wu H; Sun L
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):25-32. PubMed ID: 27444682
[TBL] [Abstract][Full Text] [Related]
47. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging.
Evangelista L; Panunzio A; Polverosi R; Ferretti A; Chondrogiannis S; Pomerri F; Rubello D; Muzzio PC
Biomed Pharmacother; 2012 Sep; 66(6):448-53. PubMed ID: 22902054
[TBL] [Abstract][Full Text] [Related]
48. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
Kaddu-Mulindwa D; Altmann B; Held G; Angel S; Stilgenbauer S; Thurner L; Bewarder M; Schwier M; Pfreundschuh M; Löffler M; Menhart K; Grosse J; Ziepert M; Herrmann K; Dührsen U; Hüttmann A; Barbato F; Poeschel V; Hellwig D
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3550-3559. PubMed ID: 33928400
[TBL] [Abstract][Full Text] [Related]
49. Usefulness of (18)F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma.
Lee Y; Hwang KH; Hong J; Park J; Lee JH; Ahn JY; Kim JH; Lee H; Kim SG; Shin JY
Nucl Med Mol Imaging; 2012 Dec; 46(4):269-77. PubMed ID: 24900074
[TBL] [Abstract][Full Text] [Related]
50. Nonossifying fibroma can mimic residual lymphoma in FDG PET: additional value of combined PET/CT.
von Falck C; Rosenthal H; Gratz KF; Galanski M
Clin Nucl Med; 2007 Aug; 32(8):640-2. PubMed ID: 17667441
[TBL] [Abstract][Full Text] [Related]
51. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
52. Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma.
Badr S; Kotb M; Elahmadawy MA; Moustafa H
Clin Nucl Med; 2018 Dec; 43(12):e428-e438. PubMed ID: 30358625
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.
Zhou Z; Chen C; Li X; Li Z; Zhang X; Chang Y; Lu L; Cui Y; Ma Y; Zhang M
Ann Hematol; 2015 Jun; 94(6):963-7. PubMed ID: 25547320
[TBL] [Abstract][Full Text] [Related]
54. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
55. PET/MRI for the evaluation of patients with lymphoma: initial observations.
Heacock L; Weissbrot J; Raad R; Campbell N; Friedman KP; Ponzo F; Chandarana H
AJR Am J Roentgenol; 2015 Apr; 204(4):842-8. PubMed ID: 25794075
[TBL] [Abstract][Full Text] [Related]
56. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
57. The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma.
Kim HY; Kim JS; Choi DR; Kim HS; Kwon JH; Jang GD; Kim JH; Jung JY; Song HH; Lee YK; Min SK; Hwang HS; Kim HJ; Zang DY; Kim HJ
Cancer Res Treat; 2015 Jul; 47(3):458-64. PubMed ID: 25648095
[TBL] [Abstract][Full Text] [Related]
58. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
59. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?
Adams HJ; Kwee TC; de Keizer B; Fijnheer R; de Klerk JM; Littooij AS; Nievelstein RA
Ann Oncol; 2014 May; 25(5):921-7. PubMed ID: 24351400
[TBL] [Abstract][Full Text] [Related]
60. The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers.
Tsai CC; Tsai CS; Ng KK; Lai CH; Hsueh S; Kao PF; Chang TC; Hong JH; Yen TC
Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1674-83. PubMed ID: 12937950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
